Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
193 hedge funds and large institutions have $581M invested in Sage Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 76 increasing their positions, 54 reducing their positions, and 40 closing their positions.
363% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $2.18M
41% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 54
5% less funds holding
Funds holding: 204 → 193 (-11)
8.37% less ownership
Funds ownership: 97.3% → 88.92% (-8.4%)
20% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 40
47% less capital invested
Capital invested by funds: $1.1B → $581M (-$516M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$11.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.52M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.38M |
| 5 |
Renaissance Technologies
New York
|
+$6.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$60.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$25.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.9M |
| 4 |
SC
Samlyn Capital
New York
|
-$11.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.14M |
SAGE Hedge Fund Activity: Q2 2024 in Review
193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2024, worth a combined $581M — down 47% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of SAGE and 32 opened new positions — a net loss of 8 holders — while 54 trimmed existing stakes and 76 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $11.1M. The largest seller was Wellington Management Group, cutting an estimated $60.4M.
- 193 institutional investors held Sage Therapeutics (SAGE) as of Q2 2024, down from 204 in Q1 2024.
- Funds reported $581M of Sage Therapeutics stock for Q2 2024, down 47% quarter-over-quarter.
- 32 funds opened new Sage Therapeutics positions in Q2 2024 and 40 closed out, a net change of -8 holders.
- The largest Sage Therapeutics buyer in Q2 2024 was Jacobs Levy Equity Management, an estimated $11.1M added.
- The largest Sage Therapeutics seller in Q2 2024 was Wellington Management Group, an estimated $60.4M sold.
Based on aggregated 13F filings for Q2 2024.